• Je něco špatně v tomto záznamu ?

Low SMARCD3 expression is associated with poor prognosis in patients with prostate cancer

IE. Ertl, U. Lemberger, P. Rajwa, P. Petrov, ST. Mayer, G. Timelthaler, B. Englinger, R. Brettner, N. Garstka, E. Compérat, L. Kenner, SF. Shariat

. 2025 ; 85 (2) : 181-190. [pub] 20241023

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc25002833

Grantová podpora
17083 "Margaretha-Hehberger-Stiftung", embedded in the "Medizinisch-Wissenschaftlicher Fonds des Bürgermeisters der Bundeshauptstadt Wien", Vienna, Austria

BACKGROUNDS: SWI/SNF complexes represent a family of multi-subunit chromatin remodelers that are affected by alterations in >20% of human tumors. While mutations of SWI/SNF genes are relatively uncommon in prostate cancer (PCa), the literature suggests that deregulation of various subunits plays a role in prostate tumorigenesis. To assess SWI/SNF functions in a clinical context, we studied the mutually exclusive, paralogue accessory subunits SMARCD1, SMARCD2, and SMARCD3 that are included in every known complex and are sought to confer specificity. METHODS: Performing immunohistochemistry (IHC), the protein levels of the SMARCD family members were measured using a tissue microarray (TMA) comprising malignant samples and matching healthy tissue of non-metastatic PCa patients (n = 168). Moreover, IHC was performed in castration-resistant tumors (n = 9) and lymph node metastases (n = 22). To assess their potential role as molecular biomarkers, SMARCD1 and SMARCD3 protein levels were correlated with clinical parameters such as T stage, Gleason score, biochemical recurrence, and progression-free survival. RESULTS: SMARCD1 protein levels in non-metastatic primary tumors, lymph node metastases, and castration-resistant samples were significantly higher than in benign tissues. Likewise, SMARCD3 protein expression was elevated in tumor tissue and especially lymph node metastases compared to benign samples. While SMARCD1 levels in primary tumors did not exhibit significant associations with any of the tested clinical parameters, SMARCD3 exhibited an inverse correlation with pre-operative PSA levels. Moreover, low SMARCD3 expression was associated with progression to metastasis. CONCLUSIONS: In congruence with previous literature, our results implicate that both SMARCD1 and SMARCD3 may exhibit relevant functions in the context of prostate tumorigenesis. Moreover, our approach suggests a potential role of SMARCD3 as a novel prognostic marker in clinically non-metastatic PCa.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25002833
003      
CZ-PrNML
005      
20250206103908.0
007      
ta
008      
250121s2025 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/pros.24815 $2 doi
035    __
$a (PubMed)39442954
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Ertl, Iris E $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria $1 https://orcid.org/0000000275649694
245    10
$a Low SMARCD3 expression is associated with poor prognosis in patients with prostate cancer / $c IE. Ertl, U. Lemberger, P. Rajwa, P. Petrov, ST. Mayer, G. Timelthaler, B. Englinger, R. Brettner, N. Garstka, E. Compérat, L. Kenner, SF. Shariat
520    9_
$a BACKGROUNDS: SWI/SNF complexes represent a family of multi-subunit chromatin remodelers that are affected by alterations in >20% of human tumors. While mutations of SWI/SNF genes are relatively uncommon in prostate cancer (PCa), the literature suggests that deregulation of various subunits plays a role in prostate tumorigenesis. To assess SWI/SNF functions in a clinical context, we studied the mutually exclusive, paralogue accessory subunits SMARCD1, SMARCD2, and SMARCD3 that are included in every known complex and are sought to confer specificity. METHODS: Performing immunohistochemistry (IHC), the protein levels of the SMARCD family members were measured using a tissue microarray (TMA) comprising malignant samples and matching healthy tissue of non-metastatic PCa patients (n = 168). Moreover, IHC was performed in castration-resistant tumors (n = 9) and lymph node metastases (n = 22). To assess their potential role as molecular biomarkers, SMARCD1 and SMARCD3 protein levels were correlated with clinical parameters such as T stage, Gleason score, biochemical recurrence, and progression-free survival. RESULTS: SMARCD1 protein levels in non-metastatic primary tumors, lymph node metastases, and castration-resistant samples were significantly higher than in benign tissues. Likewise, SMARCD3 protein expression was elevated in tumor tissue and especially lymph node metastases compared to benign samples. While SMARCD1 levels in primary tumors did not exhibit significant associations with any of the tested clinical parameters, SMARCD3 exhibited an inverse correlation with pre-operative PSA levels. Moreover, low SMARCD3 expression was associated with progression to metastasis. CONCLUSIONS: In congruence with previous literature, our results implicate that both SMARCD1 and SMARCD3 may exhibit relevant functions in the context of prostate tumorigenesis. Moreover, our approach suggests a potential role of SMARCD3 as a novel prognostic marker in clinically non-metastatic PCa.
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    12
$a nádory prostaty $x patologie $x metabolismus $x genetika $7 D011471
650    _2
$a prognóza $7 D011379
650    _2
$a senioři $7 D000368
650    12
$a chromozomální proteiny, nehistonové $x genetika $x metabolismus $7 D002868
650    _2
$a lidé středního věku $7 D008875
650    12
$a nádorové biomarkery $x genetika $x metabolismus $7 D014408
650    _2
$a transkripční faktory $x genetika $x metabolismus $7 D014157
650    _2
$a lymfatické metastázy $7 D008207
650    _2
$a lokální recidiva nádoru $x patologie $x metabolismus $x genetika $7 D009364
650    _2
$a stupeň nádoru $7 D060787
650    _2
$a imunohistochemie $7 D007150
650    _2
$a nádory prostaty rezistentní na kastraci $x patologie $x genetika $x metabolismus $7 D064129
655    _2
$a časopisecké články $7 D016428
700    1_
$a Lemberger, Ursula $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
700    1_
$a Rajwa, Pawel $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria $u Second Department of Urology, Centre of Postgraduate Medical Education, Warsaw, Poland $1 https://orcid.org/0000000340736584
700    1_
$a Petrov, Patrik $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
700    1_
$a Mayer, Stefan T $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
700    1_
$a Timelthaler, Gerald $u Center for Cancer Research, Medical University of Vienna, Vienna, Austria
700    1_
$a Englinger, Bernhard $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria $u Center for Cancer Research, Medical University of Vienna, Vienna, Austria
700    1_
$a Brettner, Robert $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
700    1_
$a Garstka, Nathalie $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
700    1_
$a Compérat, Eva $u Department of Pathology, Medical University of Vienna, Vienna, Austria
700    1_
$a Kenner, Lukas $u Department for Experimental and Laboratory Animal Pathology, Clinical Institute of Pathology, Vienna, Austria $u Unit of Laboratory Animal Pathology, University of Veterinary Medicine Vienna, Vienna, Austria $u Christian Doppler Laboratory for Applied Metabolomics, Medical University Vienna, Vienna, Austria $u Center for Biomarker Research in Medicine (CBmed), Graz, Styria, Austria
700    1_
$a Shariat, Shahrokh F $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria $u Department of Urology, Weill Cornell Medical College, New York, New York, USA $u Department of Urology, University of Texas Southwestern, Dallas, Texas, USA $u Department of Urology, Second Faculty of Medicine, Charles University, Prag, Czech Republic $u Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria $u Research Center for Evidence Medicine, Urology Department, Tabriz University of Medical Sciences, Tabriz, Iran $u Division of Urology, Department of Special Surgery, Jordan University Hospital, The University of Jordan, Amman, Jordan
773    0_
$w MED00010484 $t The Prostate $x 1097-0045 $g Roč. 85, č. 2 (2025), s. 181-190
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39442954 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250121 $b ABA008
991    __
$a 20250206103904 $b ABA008
999    __
$a ok $b bmc $g 2262934 $s 1238840
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 85 $c 2 $d 181-190 $e 20241023 $i 1097-0045 $m The Prostate $n Prostate $x MED00010484
GRA    __
$a 17083 $p "Margaretha-Hehberger-Stiftung", embedded in the "Medizinisch-Wissenschaftlicher Fonds des Bürgermeisters der Bundeshauptstadt Wien", Vienna, Austria
LZP    __
$a Pubmed-20250121

Najít záznam

Citační ukazatele

Možnosti archivace